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scan 1 yr earlier prior to treatment showed pulmonary fibrosis
suggestive of UIP, with no ground-glass change.
She presented with a 2-week-history of breathlessness after 12
injections (6 weeks) of etanercept, 25mg twice a week. There was
no evidence of infection or heart failure. CXR showed new diffuse
reticulonodular shadowing. CT pulmonary angiography (CTPA)
confirmed widespread ground-glass change with no evidence of
pulmonary embolism.
She was treated with broad spectrum intravenous antibiotics.
The etanercept and methotrexate were stopped. Despite this and
adding methylprednisolone 500mg/day for 3 days and changing
antibiotics, she developed worsening hypoxia and was intubated.
Bronchoalveolar lavage showed no evidence of TB, bacterial or
pneumocystis Carinii infection.
She developed metabolic acidosis, progressive renal failure and
later cardiac arrhythmias, and despite intensive treatment she died.
Both our patients had pre-existing lung disease, they had
enquiry into respiratory symptoms at 3 month intervals and
annual CXR prior to the commencement of etanercept and were
symptomatically stable. Also, both were on methotrexate and both
developed acute respiratory symptoms within 3 and 6 weeks of
commencing etanercept, respectively, which culminated in accel-
erated interstitial lung disease. The patient with COPD presented
earlier and recovered quickly with oral steroids alone
after discontinuing etanercept and subsequently was able to
recommence methotrexate 25mg/week with adequate joint disease
control but no recurrence of respiratory symptoms. The patient
with poorer respiratory reserve developed progressive lung disease
and died despite aggressive treatment.
Lung disease is a well-known complication of methotrexate, and
cases of accelerated methotrexate pneumonitis are also reported
within 2–3 doses of infliximab. Our patient who survived restarted
methotrexate safely, hence we do not postulate this as a cause [1].
Infliximab has been reported to accelerate lung nodulosis [2, 3],
and it has been reported as causing a reversible, biopsy proven,
non-caseating granulomatous lung disease in RA [4]. In both our
patients, lung biopsies were taken, which may have been the
histological change of the respiratory disease. Four further cases
of reversible non-caseating granulomatous reaction temporally
related to etanercept therapy have also been reported, two of which
had previous pulmonary fibrosis [5]. Our two cases demonstrate a
little-known complication of etanercept, one of which was fatal. It
is noticeable that the patient who died also had rheumatoid lung
disease, whilst the patient with COPD survived. Previously reports
from the Biologics register [6], and published reports have raised
the concern of increased mortality in patients with RA and
pre-existing rheumatoid lung disease on azathiaprine when
anti-TNF was added [7]. On the basis of these two cases caution
needs to be extended to those with pre-existing lung disease, taking
methotrexate when etanercept is added, particularly if the lung
disease is due to rheumatoid involvement. Extra caution should be
taken in patients with rheumatoid lung and poor respiratory
reserve. Patients should be prompted to contact the rheumatology
department if symptoms of acute breathlessness occur, especially
soon after the introduction of etanercept.
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Detection of tuberculosis by extensive screening in a patient
with rheumatoid arthritis prior to anti-TNF- therapy
SIR, TNF- blocking agents have seen increasing use in the
treatment of systemic inflammatory diseases such as rheumatoid
arthritis (RA). An association of anti-TNF- agents with the
occurrence of mycobacterial infections (MTBI), with a high
proportion of extrapulmonary and disseminated cases, has been
noted [1, 2]. The article by Horsburgh [3] highlights the public
health consequences of MTBI in the setting of anti-TNF-
therapy. It is recommended to exclude MTBI before anti-TNF-
therapy and to give prophylactic isoniazid (INH) if latent MTBI
(LMTBI) is suspected [4]. The use of INH in patients >50 yrs is
associated with a considerable mortality of 2.3% [5]. In addition,
the effectiveness of prophylactic INH therapy is in the range
of 25–92%, depending on underlying disease, compliance and
type of study [6]. Therefore, we decided to implement a more
stringent pre-treatment screening protocol. This encompasses
conventional radiographs of the chest in two planes and, if
results were questionable, a CT scan. The tuberculin skin test
(TST) was performed with two IU injected intracutaneously
according to the standard procedure in Switzerland. A reading
was taken 48–72 h later, an induration of 5mm was considered
positive. If negative, the TST was repeated after 7–10 days,
with identical criteria applied for reading. If the TST was positive,
and/or imaging of the chest suspicious, bronchosopy with lavage
and brushings for cultures and nucleic acid amplification tests
(NAAT) for mycobacteria, and cultures and NAAT of the urine
were performed.
From September 2002 until July 2004, 17 patients with the
indication for anti-TNF- therapy were screened according to
this procedure. Six had further examinations, of which three were
based on the chest radiograph and three on a positive TST.
Among the latter, the following case of LMTBI was detected.
A 76-year-old woman with RA of 14 years duration, who
had persistent erosive disease despite various disease-modifying
anti-rheumatic drugs (DMARDs), qualified for anti-TNF-
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Key message
 When anti-TNF agents are added,
patients with pre-existing rheumatoid
lung disease taking methotrexate, are
at a risk of acute pulmonary disease
progression.
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treatment. Apart from her age, and the use of DMARDs and low-
dose glucocorticosteroids, there were no apparent risk factors for
tuberculosis, and clinical signs of an acute or chronic infection
were absent. The chest X-ray (Fig. 1) showed no evidence of
MTBI, but the TST provoked an induration of 10mm in
diameter. Bronchoscopy was unremarkable and fluorescence
microscopy of the specimens and of the urine for mycobacteria
were negative. However, cultures and NAATs (Cobas Amplicore
MTB) of the tracheobronchial lavage and of the urine identified
Mycobacterium africanum, which was sensitive to rifampicin
(RIF), INH, ethambutol (ETB) and pyrazinamide (PZA).
Possible active foci in the chest and abdomen could not
be detected by a CT scan of the chest and abdominal
ultrasonography. A tuberculostatic regimen with INH 50mg,
PZA 300mg and RIF 120mg daily for 2 months followed by
INH 100mg and RIF 150mg daily for 7 months was given
under continued weekly methotrexate and daily low-dose pred-
nisone. Culture and PCR for mycobacteria in the urine turned
negative.
This case raises several questions relating to anti-TNF-
therapy. First, how adequate are the current recommendations
for the detection of LMTBI? Second, how appropriate is
prophylactic INH to prevent the possible activation of LMTBI
under anti-TNF- therapy? Third, what is the cost–benefit
ratio of INH prophylaxis in view of potential toxicity and
drug resistance? Fourth, are there any differences between the
available anti-TNF- agents? Fifth, will the introduction of T-cell
stimulation test with MTB peptides improve the screening
procedure for LMTBI [7, 8]? The answers will establish whether
more extensive procedures to exclude LMTBI before anti-TNF-
therapy and treatment as necessary are superior to prophylactic
INH, with the exposure of patients not needing it, and the
potential drawback of resistance. Until these questions are
resolved, astute clinical assessment under consideration of the
recommendations of national professional societies must guide
the handling of this issue.
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Re: Touch screen computer systems in the rheumatology
clinic offer a reliable and user-friendly means of collecting
quality-of-life and outcome data from patients with
rheumatoid arthritis
SIR, With great interest we read the article by Greenwood et al. [1]
on the use of touch screen computer systems in the rheumatology
clinic. They demonstrated that the use of touch screen ques-
tionnaires is a feasible way of data collection in a rheumatology
clinic. Another application of interactive computer systems in
rheumatology clinics may be the provision of health information
[2]. It was found earlier that patients with chronic rheumatic
diseases use the Internet primarily to search for information about
the disease and its treatment [3]. We would like to share our
experience with an interactive patient-information kiosk.
In July 2005, an interactive patient-information kiosk was
placed in the waiting area of the rheumatology out-patient clinic.
The kiosk had a user-friendly design and provided access to
one specific website via a high-speed Internet connection. This
website (www.reumanet.nl) contained general information and
address/telephone/e-mail directories regarding various regional
healthcare services [4] and organizations for patient with
rheumatic diseases. Moreover, links to 65 selected other related
websites were included. An instruction chart on how to use the
kiosk and an information leaflet about the website were present
FIG. 1. Radiograph of the chest without signs of latent
mycobacterial infection.
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